The aim is to explore the use of secondary metabolites from Lobaria pulmonaria for treating multidrug-resistant tuberculosis.
Examined the traditional use of Lobaria pulmonaria in tuberculosis treatment.
Identified key metabolic enzymes targeted by secondary metabolites.
Investigated the efficacy of these metabolites against multidrug-resistant strains.
Secondary metabolites from Lobaria pulmonaria show potential in inhibiting key metabolic enzymes.
These findings highlight a novel strategy for combating multidrug-resistant tuberculosis.
Abstract
Numerous cultures have traditionally utilised the foliose lichen Lobaria pulmonaria (L.) Hoffm. (“Oak Lung” or “Lungs of Oak” in English; family: Lobariaceae) as a Tuberculosis (Tb) treatment.